8-K
filed January 8, 2024, 6:59 PM ET
ticker CORT
CIK 0001088856
earnings
confidence high
sentiment positive
materiality 0.80
Corcept reports Q4 2023 revenue $135.4M (+31% YoY); guides 2024 rev $600-630M; announces $200M buyback
CORCEPT THERAPEUTICS INC
2023-FY EPS reported
$0.94
revenue$482,375,000
- Q4 2023 revenue $135.4M, up 31% YoY from $103.1M; full year $482.4M, up 20% from $401.9M.
- 2024 revenue guidance $600-630 million; cash and investments $425.4M at Dec 31, 2023.
- Board authorized $200M stock repurchase program; effective Jan 10, 2024.
- Results are preliminary, unaudited, and subject to audit adjustments.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
CORCEPT THERAPEUTICS INC reported year ended December 31, 2023 results: revenue $482.4 million.
- Period
- year ended December 31, 2023
- Revenue
- $482.4 million
- Result
- preliminary results
Exact text from the filing
Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
CORCEPT THERAPEUTICS INC reported quarter ended December 31, 2023 results: revenue $135.4 million.
- Period
- quarter ended December 31, 2023
- Revenue
- $135.4 million
- Result
- preliminary results
Exact text from the filing
Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
CORCEPT THERAPEUTICS INC reported fiscal year 2024 results: revenue $600 – $630 million. Guidance initiated.
- Period
- fiscal year 2024
- Revenue
- $600 – $630 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Financial Update • Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 • Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 • 2024 revenue guidance of $600 – $630 million • Cash and investments of $425.4 million as of December 31, 2023 • Announcement of $200 million stock repurchase program “As the true prevalence of hypercortisolism and its devastating impact become better understood, physicians are identifying and treating more patients
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.